AI-discovered drug receives US FDA orphan drug designation
Insilico Medicine receives Orphan Drug Designation from the US FDA after successful Phase I clinical trial results for their AI-discovered drug INS018_055.
When we talk about Artificial Intelligence (AI) in drug discovery, it can still seem like a thing of the future, something the industry is still working towards. However, the AI-driven drug discovery company Insilico Medicine (Pak Shek Kok, Hong Kong) has firmly brought AI drug discovery into the present, with it’s recent US FDA approval for INS018_055 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) under an orphan designation.
Insilico Medicine runs a clinical-stage end-to-end generative artificial intelligence platform called Pharma.AI. The platform is used to discover potential drugs that can be brought to market, in this case a first-in-class small molecule inhibitor that could be used for the treatment of IPF. IPF is a chronic and irreversible lung disease, characterised by the progressive decline in function in the lungs and can lead to diminished respiratory function.
“We are pleased to announce that Insilico has achieved numerous drug discovery milestones and provided new clinical hope using generative AI,” stated Alex Zhavoronkov, Founder and CEO of Insilico Medicine. “We are progressing the global clinical development of the program at top speed to allow patients with fibrotic diseases to benefit from this novel therapeutic as soon as possible.”
To bring the completely novel drug from conception to clinical viability, Insilico Medicine nominated INS018_055 as the preclinical candidate for IPF, the first project of its kind from the company. By February 2022 enrolment had begun for a Phase I clinical trial in New Zealand, and in China by May of the same year. The trials were soon completed and the initial results suggested that INS018_055 had promising levels of safety, tolerability, and pharmacokinetics. Spurred on by this, Insilico are hoping to launch a multi-centre Phase II clinical trial in 2023, on a more global scale.
“Our commitment to treating patients with idiopathic pulmonary fibrosis is reflected in the FDA’s decision to grant orphan drug designation to INS018_055,” explained Sujata Rao, Senior Vice President, Head of Clinical Development at Insilico Medicine. “We are working to advance novel treatment for IPF as we continue clinical investigation into this devastating disease.”
In the USA there are more than 7,000 identified rare diseases, defined as a disease or condition that affects less than 200,000 people. As such, for many pharmaceutical companies there is unfortunately not much motivation to research and develop new drugs as this wouldn’t be financially viable. The US FDA’s orphan drug designation programme however, encourages and supports the development of these drugs. For Insilico, receiving the orphan designation for INS018_055 will mean the expedited commercialisation of the product by including eligibility for federal grants, tax credits for qualified clinical trials, prescription drug user fee exemptions, and a seven-year marketing exclusivity period upon full US FDA approval.
Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine commented:
“The FDA’s orphan drug designation for the IPF indication is an important milestone in the development of INS018_055. Insilico scientists are now further advancing clinical validation and accelerating the project to meet clinical needs and benefit patients worldwide.”
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance